Actively Recruiting
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Led by University of Zurich · Updated on 2026-03-16
50
Participants Needed
1
Research Sites
258 weeks
Total Duration
On this page
Sponsors
U
University of Zurich
Lead Sponsor
U
University Hospital, Zürich
Collaborating Sponsor
AI-Summary
What this Trial Is About
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy. This assay combines five components for longitudinal profiling of each patient. The goal of the trial is that the assay can be completed (feasibility). This comprehensive assay integrates five key components including circulating tumor DNA (CAPPseq), inflammation markers from peripheral blood tests (InflaMIX), PET CT imaging parameters, immune cell profiles (flow cytometry), and performance status (ECOG). Ultimately, this tool could improve treatment selection, and guide more personalized therapy decisions for lymphoma patients receiving CAR T cells.
CONDITIONS
Official Title
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before any trial procedures
- Age 18 years or older
- Diagnosis of relapsed or refractory B-cell lymphoma as per WHO 2022 classification
- Measurable disease according to disease-specific criteria such as Lugano 2014
- Planned treatment with CD19-directed CAR T cell therapy per clinical standard
- Willingness to donate peripheral blood and biopsy samples at specified visits
You will not qualify if you...
- Any condition preventing start of CD19-directed CAR T cell therapy (e.g., pregnancy, breastfeeding, infections)
- Medical or psychological conditions that interfere with study participation as judged by the physician
- Unwillingness or inability to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Universityhospital Zurich, Department of Medical Oncology and Hematology
Zurich, Canton of Zurich, Switzerland, 8091
Actively Recruiting
Research Team
T
Thorsten Zenz, Prof. Dr. med.
CONTACT
S
Stefanie Kreutmair, Dr. med.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here